Search Results for:
-
REFORM ON ROLLERCOASTER THROUGH CONGRESS
In the coming weeks and months, legislators will make increasingly painful political and financial choices on issues such as universal coverage, employer mandates, prescription drug benefits and new taxesBioWorld Today | Wednesday, April 13, 1994 -
ADMINISTRATION REPS DEFEND CLINTON HEALTH PLAN AT HEARING
Smits said that the addition of a prescription drug benefit to Medicare would create a huge new market for drugs, but that the government as a buyer will need tools for negotiating prices with sellers in that marketBioWorld Today | Friday, March 18, 1994 -
WASHINGTON NEWS BRIEFS KESSLER DEFENDS FDA'S 1995 BUDGET
User fees collected from the prescription drug industry would rise from the estimated $56 million to be collected in 1994 to $79 million in 1995...Under questioning by congressional representatives about the effectiveness of user fees, Kessler argued that proceeds from the Prescription Drug User Fee Act of 1992 has allowed FDA to recruit 180 additional medical reviewers to dateBioWorld Today | Friday, March 18, 1994 -
STARK'S PLAN GAINS CREDIBILITY
Stark's plan, currently under consideration by the Health Subcommittee of the House Ways and Means Committee, provides for universal coverage of all uninsured Americans and extends prescription drug coverage to Medicare recipients -- two core reform elements that many believed would be fiscally irreconcilable...A spokesman for Stark said the congressman is "strongly committed to addressing the problem of prescription drug prices" and won't be bargaining with that chip any time soon. -- LisaBioWorld Today | Tuesday, March 15, 1994 -
IS BIO OVERSIMPLIFYING BIOTECH FINANCING 'CRISIS'?
WASHINGTON -- At a recent hearing on prescription drug pricing before the Health and Environment Subcommittee of the House Energy and Commerce Committee, Genentech Inc.'s chief executive officer, Kirk Raab, argued the biotechnology industry's case against perceived price control elements in President Clinton's health care reform proposalBioWorld Today | Thursday, March 3, 1994 -
GENENTECH'S PULMOZYME LAUNCHED IN U.K.
Pulmozyme was unanimously recommended for approval by the European Committee for Proprietary Medicinal Products (CPMP) in January, and was subsequently licensed by the U.K. Medicines Control Agency, the government agency that oversees prescription drugs under Britain's single-payer programBioWorld Today | Wednesday, March 2, 1994 -
FDA HIRING FREEZE LIFTED
The agencywide freeze prevented FDA from hiring personnel needed to implement the Prescription Drug User Fee Act, even though the jobs were to be financed by that programBioWorld Today | Tuesday, January 18, 1994 -
CYGNUS COLLABORATES WITH WYETH-AYERST
In October, Cygnus signed an agreement with Procter & Gamble to apply its drug-delivery technology for an unspecified product sold directly to the consumer (as opposed to a prescription drugBioWorld Today | Wednesday, December 29, 1993 -
PENEDERM RAISES $22M IN IPO
In September, Penederm submitted new drug applications with the FDA for its first prescription drug products, retinoic acid formulations for treating acneBioWorld Today | Thursday, November 4, 1993 -
PHYTOPHARMACEUTICALS PACT FOR PLANT-BASED DRUGS
According to Brian Boom, vice president for botanical sciences at NYBG, one-quarter of all prescription drugs used in the U.SBioWorld Today | Tuesday, October 26, 1993 -
INTERNEURON LAUNCHES, TESTS SUPPLEMENTS
who swallowed graduated doses of the prescription drug while on a semi-starvation diet of 1,200 caloriesBioWorld Today | Tuesday, October 19, 1993 -
CLINTON ADAMANT ABOUT RESTRAINING DRUG COSTS
Clinton acknowledged the life-saving and cost-reducing potential of biotechnology drugs, and may have been referring to motivation for research when she said that the payment for prescription drugs under the health-care plan "would greatly enhance the money going to our pharmaceutical drug manufacturersBioWorld Today | Wednesday, September 29, 1993 -
BIO REPORT ATTACKS PRICE CONTROLS
He compiled a list of over 90 popular prescription drugs that have increased in price much faster than the inflation rate for the first six months of 1993BioWorld Today | Monday, September 20, 1993 -
PMA SURVEY: ELEVEN PRODUCTS AWAIT REVIEW BY FDA
Releasing the survey at a press conference in Washington, D.C., PMA used the event as a forum to speak against mandatory price controls on prescription drugsBioWorld Today | Friday, September 17, 1993 -
OPPOSITION FORMS AGAINST MEDICAID FORMULARIES
The easy thing to do is to write a prescription for a drug that the state allows without prior authorizationBioWorld Today | Thursday, July 8, 1993 -
CONGRESS EXPECTED TO OK USER FEE APPROPRIATIONS
WASHINGTON -- The U.S. House of Representatives and Senate are expected to approve supplemental appropriations for the Prescription Drug User Fee Act todayBioWorld Today | Friday, July 2, 1993 -
AGOURON AND SYNTEX INK $15M DEAL
In fact, Syntex has been marketing Naprosyn, one of its prescription drugs for treating the pain and inflammation of arthritis, since 1976, according to Linda Thomas, Syntex's manager of media relationsBioWorld Today | Wednesday, June 9, 1993 -
DRUG PRICING REVIEW BOARD REPORTED
The Times gleaned from "work papers" of the Hillary Clinton Health Care Task Force that "the board would collect information about prices, and it would establish guidelines as to a reasonable price for prescription drugs that have no therapeutic alternativeBioWorld Today | Tuesday, May 18, 1993 -
NIH LICENSING AIDS DRUGS
These compounds are a series of eight halogen-substitution nucleoside analogs, chemical kin to, but different from, the current anti-AIDS prescription drugs, AZT and ddI (dideoxyinosineBioWorld Today | Thursday, April 8, 1993 -
FEW PRODUCTS IN SECOND-QUARTER PIPELINE
He sees the drug price issue targeted to retired people who, as a group, rely more on long- term prescription drugs, while the first trial balloon raised about child vaccines generated emotional appeal for the plight of youngstersBioWorld Today | Tuesday, April 6, 1993
Category
Current Filters
- xPrescription Drug
Related Keywords
Categories
- x BioWorld Today (781)
- x BioWorld Insight (142)
- x Bio Perspectives (46)
- x BioWorld International (39)
- x State of the Industry Report (24)
- x Top 25 Drug Report (13)
- x BioWorld Snapshots (4)
- x RNAi Report (1)
- x BioWorld Genomics Review (1)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.